This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Mixed cortical and subcortical vascular dementia혼합형 피질 및 피질하 혈관성 치매

Contents and key points
ItemDetails
A. Classification codesICD-10: F01.3 | Special Copayment Reduction: V810 (severe intractable disease, 5 years)
B. SynonymsNo separate synonyms; mixed vascular dementia; cortical and subcortical combined vascular dementia
C. Adult onsetYes — middle-aged to older adults; mixed cortical and subcortical vascular lesions.
1-13. Main textVascular dementia in which cortical infarcts (F01.1) and subcortical small vessel lesions (F01.2) coexist; clinical features are a mixture of the characteristics of the two types; epidemiology, mechanisms, and treatment follow an integrated approach of F01.1 and F01.2.

1. History

F01.3 is the ICD-10 code classifying vascular dementia in which cortical infarcts (F01.1, mainly cortical in multi-infarct dementia) and subcortical small vessel lesions (F01.2, Binswanger type) are present simultaneously. In clinical reality, vascular dementia involving purely cortical or purely subcortical areas only is uncommon, and the recognition that most vascular dementia patients have mixed cortical and subcortical lesions has spread with the availability of MRI. The NINDS-AIREN criteria (1993) also recognize various vascular pathology patterns of vascular dementia and include the mixed cortical-subcortical lesion type. The VasCog 2014 criteria assess mainly the overall vascular lesion burden rather than the distinction between cortical and subcortical lesions. In clinical research and medical statistics, F01.3 accounts for a considerable share of the vascular dementia classification.


2. Causes

F01.3 is the case in which a large-vessel or cardioembolic mechanism causing cortical infarcts (see F01.1) and subcortical ischemic changes due to small vessel lesions (see F01.2) coexist in the same patient. Hypertension is a common risk factor contributing to both mechanisms. Diabetes, atrial fibrillation, smoking, and dyslipidemia act in combination to cause cortical and subcortical lesions simultaneously. The likelihood of mixed lesions increases with older age, and in dementia patients aged 80 and over, mixed vascular pathology is more common than pure vascular pathology.


3. Genetics

The genetic background of F01.3 includes the genetic backgrounds of both F01.1 and F01.2. APOE ε4, CADASIL (NOTCH3), and blood pressure- and thrombosis-related gene polymorphisms (ACE, MTHFR, Factor V Leiden) are involved. In mixed lesions, polygenic risk factors often act in an overlapping manner.


4. General epidemiology

In clinical practice, the mixed type is observed more commonly than pure cortical or subcortical vascular dementia. About 40-60% of vascular dementia patients are estimated to correspond to F01.3, with mixed cortical and subcortical lesions. Mixed vascular lesions are likely to occur in patients with older age, hypertension, diabetes, and atrial fibrillation.


5. Pathophysiology

Network disconnection from cortical infarcts and fronto-subcortical circuit dysfunction from subcortical small vessel lesions act in combination, affecting both cortical functions (memory, language, visuospatial) and subcortical functions (executive function, processing speed, gait). When the two mechanisms act synergistically, cognitive decline is more severe than with either lesion alone. The combination of blood-brain barrier damage, neuroinflammation, and amyloid angiopathy makes the pathogenesis of mixed vascular dementia even more complex.


6. Symptoms

Patients with F01.3 show a mixture of memory impairment, aphasia, and visuospatial impairment from cortical infarcts and executive function decline, reduced processing speed, and gait disturbance from subcortical lesions. They may show a mixed pattern combining stepwise progression (the cortical infarct component) and gradual progression (the subcortical component). Depression, apathy, and emotional incontinence are common, and gait disturbance and urinary incontinence may appear relatively early. Focal neurological deficits (hemiparesis, language disorder) accompany small vessel symptoms (gait instability, short-stepped gait).


7. Signs

On brain MRI, a mixture of cortical infarcts, subcortical WMH, and lacunar infarcts is characteristic. When three findings are observed simultaneously on brain MRI — cortical infarcts (FLAIR hyperintensity, lobar distribution), WMH (extensive white matter degeneration), and multiple lacunar infarcts (subcortical) — F01.3 is strongly suggested. On neurological examination, focal deficits such as hemiparesis are mixed with short-stepped gait, pyramidal tract signs, and dysarthria.


8. Screening

In patients with cognitive decline who have vascular risk factors, brain MRI is performed with a standard protocol (T2, FLAIR, DWI, SWI, MRA) to evaluate cortical and subcortical lesions together. Memory, language, executive function, and processing speed are assessed with the MoCA and comprehensive neuropsychological testing. Atrial fibrillation screening (ECG, Holter monitoring), carotid ultrasound, and blood tests (hyperlipidemia, diabetes, coagulation markers) are performed.


9. Diagnosis

The diagnosis of F01.3 is made by meeting dementia criteria + confirmation of cortical and subcortical vascular lesions on MRI + exclusion of other major causes. Amyloid PET or plasma/cerebrospinal fluid biomarkers are considered to exclude coexisting Alzheimer pathology (mixed dementia). The VasCog 2014 criteria or the NINDS-AIREN criteria are applied.


10. Treatment

Treatment of F01.3 integrates the treatment of F01.1 and F01.2. Strict blood pressure control (SBP <130 mmHg), diabetes management, anticoagulation for atrial fibrillation, antiplatelet agents, and statin therapy are the key to preventing recurrence. Cognitive rehabilitation, gait rehabilitation, and fall prevention programs are provided in parallel. Non-pharmacological and pharmacological treatment of behavioral and psychological symptoms and caregiver support services are provided.


11. Prognosis

F01.3 tends to show more severe cognitive and functional decline than F01.1 or F01.2 alone. The lesion burden of the two types accumulates, so dementia progresses faster and complications (falls, aspiration pneumonia, infection) occur earlier. Controlling vascular risk factors is key to slowing progression.


12. Prevention

Integrated management of multiple vascular risk factors is the key to preventing F01.3. Early detection and continuous treatment of hypertension, diabetes, and hyperlipidemia, early treatment of atrial fibrillation (anticoagulation), smoking cessation, aerobic exercise, and maintaining an appropriate weight prevent both cortical and subcortical vascular lesions. Education on recognizing stroke warning symptoms and immediate use of medical care are important.


13. References

  1. Dichgans M, Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573-591. PMID: 28154105.
  2. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. PMID: 24632990.
  3. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Neurology. 1993;43(2):250-260. PMID: 8094895.
  4. Iadecola C, Duering M, Hachinski V, et al. Vascular Cognitive Impairment and Dementia. J Am Coll Cardiol. 2019;73(25):3326-3344. PMID: 31226035.
  5. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-696. PMID: 31097385.
  6. SPRINT MIND Investigators. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019;321(6):553-561. PMID: 30688979.
  7. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia. Stroke. 2011;42(9):2672-2713. PMID: 21778438.
  8. van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003. PMID: 29446769.
  9. Pantoni L. Cerebral small vessel disease. Lancet Neurol. 2010;9(7):689-701. PMID: 20610345.
  10. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. PMID: 39096926.